Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Raymund Razonable MD

Raymund R. Razonable MD

Professor of Medicine, Mayo Clinic College of Medicine and Science, Program Director, Mayo Clinic Infectious Diseases Fellowship Program, Mayo Clinic, Rochester, Minnesota

Raymund R. Razonable, MD, is Professor of Medicine and Distinguished Clinician at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. He serves as Vice Chair of the Division of Public Health, Infectious Diseases and Occupational Medicine, and Program Director of the Infectious Diseases Fellowship Training Programs at the Mayo Clinic.

Dr. Razonable’s clinical, educational and research interests include infections related to or gan transplantation, with specific focus on cytomegalovirus infections. He has authored over 260 peer-reviewed original and review articles, more than 30 book chapters and over 200 abstracts on these topics. Since the start of the COVID-19 pandemic, Dr. Razonable focused his work on the covid-19 therapeutics. He is the physician leader of Monoclonal Antibody Treatment Program at Mayo Clinic.

Disclosures

Dr. Razonable reports the following:
  • Research grant from Roche, Regeneron and Gilead (funds paid to the institution).
  • Data and Safety Monitoring Board for Novartis.

Recent Contributions to PracticeUpdate:

  1. Sotrovimab Effects on Hospitalization and Death Among High-Risk Patients With Mild to Moderate COVID-19

Most Read This Week

Recently Updated